Federal Circuit Reviews AMP v USPTO, Patentability of Genes
Are isolated genes a product of human ingenuity or a product of nature?
Yesterday, the Federal Circuit heard oral arguments in the gene patent case Association of Molecular Pathology v. U.S. Patent and Trademark Office (aka the Myriadcase). The legal question under review is whether a gene, once "isolated" from a person's entire genetic code, is a "product of nature," and therefore ineligible for patent.
The case centers on Myriad Genetics' patents on two genes related to breast and ovarian cancer. AMP, in collaboration with American Civil Liberties Union, researchers, doctors and patients have challenged the legality of these patents, arguing, among other things, that they make it harder for women to get access to cancer screening. (For details of the case, check this overview)
The judges' decision is expected to have broad implications throughout the life science community, affecting companies, researchers and patients.
A complete recording of the oral arguments for ASSOCIATION FOR MOLECULAR V. PTO can be found here.
Inventors attending CES may bring notes and a drawing of their invention to booth 70555 to be eligible for a free patent application.
The firm’s new website will feature an enhanced resource center, responsive design, and a clean, modern look.
Members of the Security and Surveillance panel will explore the issues facing brand owners in the wake of recent data breaches at large trusted retailers, and in the light of disturbing revelations about government surveillance and back-door access to customer data.
The multiple patents for Wide Area Networks continue to expand Silver Peak's IP portfolio and their commitment to innovation.